We found that—i) underlying metabolic and cardiovascular comorbidities are most prevalent in our COVID-19 patient population and were associated with increased mortality risk along with COPD and CKD; ii) asthma did not modify mortality risk in CoV2+ patients; iii) development of AKI, AMI and ARDS secondary to COVID-19 was associated with increased risk of mortality; iv) d-dimer, CRP, IL-6, TNFα, cTnI, and BNP levels were significantly elevated in deceased individuals. The gene discussed is TNNI3; the disease is asthma.